Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population

{{article.zuoZheEn}}

PDF(169 KB)
PDF(169 KB)
Front. Med. ›› 2016, Vol. 10 ›› Issue (4) : 437-443. DOI: 10.1007/s11684-016-0472-9
RESEARCH ARTICLE

Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2016, 10(4): 437‒443 https://doi.org/10.1007/s11684-016-0472-9

References

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
Share on Mendeley
PDF(169 KB)

Accesses

Citations

Detail

Sections
Recommended

/